Shreyaskumar Patel

Professor

  • 12864 Citations
  • 58 h-Index
1989 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Shreyaskumar Patel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Sarcoma Medicine & Life Sciences
Gastrointestinal Stromal Tumors Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
trabectedin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Osteosarcoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2019

1 Citation (Scopus)

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas

Jones, R. L., Chawla, S. P., Attia, S., Schöffski, P., Gelderblom, H., Chmielowski, B., Le Cesne, A., Van Tine, B. A., Trent, J. C., Patel, S., Wagner, A. J., Chugh, R., Heyburn, J. W., Weil, S. C., Wang, W., Viele, K. & Maki, R. G., Jul 15 2019, In : Cancer. 125, 14, p. 2445-2454 10 p.

Research output: Contribution to journalArticle

Open Access
docetaxel
gemcitabine
Sarcoma
Confidence Intervals
Safety

Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Choy, E., Ballman, K., Chen, J., Dickson, M. A., Chugh, R., George, S., Okuno, S., Pollock, R., Patel, R. M., Hoering, A. & Patel, S., Jan 1 2019, In : Sarcoma. 2019, 7608743.

Research output: Contribution to journalComment/debate

Open Access
gemcitabine
Leiomyosarcoma
Sarcoma
Recurrence
Therapeutics
1 Citation (Scopus)
Osteosarcoma
Radiotherapy
Drug Therapy
Neoplasm Metastasis
Recurrence

MAGE-A3 is a clinically relevant target in undifferentiated pleomorphic sarcoma/myxofibrosarcoma

Conley, A. P., Wang, W. L., Livingston, J. A., Ravi, V., Tsai, J. W., Ali, A., Ingram, D. R., Lowery, C. D., Roland, C. L., Somaiah, N., Hwu, P., Yee, C., Subbiah, V., Futreal, A., Lazar, A., Patel, S. & Roszik, J., May 1 2019, In : Cancers. 11, 5, 677.

Research output: Contribution to journalArticle

Open Access
Sarcoma
Immunotherapy
Neoplasms
Lymphocytes
Encyclopedias